Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 11/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21090804 | 0.90 | SCN9A (0.50) | SCN9ATP53SMN1; SMN2SCN5APTPN1 | |
| SCHEMBL25791011 | 0.88 | TP53 (0.41) | TP53RAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL25791037 | 0.86 | MAPK14 (0.39) | TP53RAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL30063196 | 0.85 | MAPK14 (0.38) | SCN9ATP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL21053213 | 0.85 | MAPK14 (0.38) | SCN9ATP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL25790954 | 0.84 | GAA (0.39) | TP53RAB9ASMN1; SMN2NPC1RECQL | |
| SCHEMBL21090671 | 0.81 | SCN9A (0.49) | SCN9ATP53SMN1; SMN2SCN5AAKR1C3 | |
| SCHEMBL25790329 | 0.79 | TEAD1 (0.41) | RAB9ASMN1; SMN2NPC1BRD4BRD2 | |
| SCHEMBL21054644 | 0.77 | ABCG2 (0.46) | SCN9ATP53RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL25791053 | 0.75 | TP53 (0.46) | TP53RAB9ASMN1; SMN2NPC1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | SCN9A 1817/4885TP53 145/4885RAB9A 1922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.